Nicotine Gateway Effects on Adolescent Substance Use

Michelle Ren, MS*  
Shahrad Lotfipour, PhD†  
*University of California, Irvine, Department of Pharmaceutical Sciences, Irvine, California  
†University of California, Irvine, Department of Emergency Medicine and Pharmaceutical Sciences, Irvine, California

Section Editor: Tony Zitek, MD  
Submission history: Submitted November 11, 2018; Revision received April 15, 2019; Accepted July 1, 2019  
Electronically published August 20, 2019  
Full text available through open access at http://escholarship.org/uc/uciem_westjem  
DOI: 10.5811/westjem.2019.7.41661

INTRODUCTION

The growing use of tobacco and electronic nicotine delivery systems (“vaping”) among teenagers represents a major public health concern. Smoking is not only the leading cause of preventable death worldwide, but epidemiological, clinical, and preclinical data have also shown that adolescent exposure to tobacco or nicotine can lead to subsequent abuse of nicotine and other substances.1–19 This phenomenon is known as the gateway hypothesis.10,20,21 Furthermore, adolescents are more likely to first experiment with combustible cigarettes and/or e-cigarettes than they are marijuana.22,23 Sequence patterns of drug initiation were examined in a recent study (2015), which reported that 38.8 percent of adolescents initiate nicotine before alcohol and/or marijuana, while 21.3 percent use alcohol prior to nicotine and/or marijuana, and 8.6 percent use marijuana before nicotine and/or alcohol.23 Although previous reports highlight that the rates of cigarette smoking are decreasing in the United States (U.S.), from 20.9 percent in 2005 to 15.5 percent in 2016, current trends in teen use of electronic nicotine delivery systems (e.g., e-cigarettes, vaporizers, hookah pens) are rapidly increasing.24–26 In particular, the rate of current e-cigarette use in high school students jumped from 1.5 percent in 2011...
to 11.7 percent in 2017, then alarmingly to 20.8 percent in 2018. Among middle school students, a rise of 48 percent in e-cigarette use has also been reported from 2017 to 2018. This translates to a massive surge of an additional 1.5 million youth having been exposed to e-cigarettes in the last year alone in the U.S. The youth are often attracted to e-cigarettes due to their flavoring, easy availability, and a lack of awareness of their harmful effects. While e-cigarettes are marketed to aid in smoking cessation for adults, they have had inconsistent effects on cessation in adults and have been shown to promote smoking progression in the youth, with increased cigarette smoking in adolescents who had previously used e-cigarettes (19.1 percent) compared to those who had not (4.6 percent). In this review, we present studies that support a causal role of adolescent nicotine exposure in maladaptive alterations in reward processing during and beyond adolescence, with molecular, neurochemical, and cognitive impacts on the brain that ultimately encourage subsequent drug use.

Adolescence is a period of transition characterized by significant hormonal, psychosocial, and neural changes in rodents (postnatal day (PND) 28-42) and humans (12-18 years of age). Adolescence is a time of increased exploration and the development of social, emotional, and cognitive skills to prepare for independence of adulthood. However, adolescence is also associated with increased vulnerability to stress and risk-taking behaviors, such as sensation seeking and experimentation with recreational drugs. These age-specific behaviors are largely due to maturational changes in the brain.

During this sensitive maturational period, the brain is particularly vulnerable to the harmful effects of drugs of abuse, including tobacco and nicotine products. Nicotine is the primary psychoactive constituent in tobacco products and binds to nicotinic acetylcholine receptors (nAChRs), which are pentameric ligand-gated ion channels composed of α and β subunits (α1-7, 9-10; β1-4). nAChRs are widely distributed throughout the human and rodent brain and periphery, and are critical in the processes of the neuromuscular junction, neurotransmitter release, brain maturation, reward processing, and cognition. nAChRs are activated endogenously by acetylcholine or exogenously by nicotine, and are expressed by the majority of neuronal subtypes, including dopaminergic neurons, which facilitate drug intake and abuse. Nicotine exposure during adolescence, in particular, disrupts the normal development and expression of neuronal nAChRs, ultimately altering the function and pharmacology of the receptor subunits and changing the release of dopamine, serotonin, GABA, glutamate, and other reward-related neurotransmitters.

Many factors are recognized to contribute to the onset of teenage substance abuse, such as genetics, stress, and socioeconomic status. While various mechanisms may impact substance abuse and addiction, this review focuses on the influence of developmental nicotine exposure on long-term changes in reward neural circuitry and subsequent drug use. We highlight findings from both human and rodent studies, as animal models provide insight into human brain maturation, physiology, and behavior. We argue that the effects of nicotine are highly dependent on timing of exposure, and that nAChRs interact with other drug receptor systems to directly mediate reward and reinforcement.

Clinical Implications
The escalation in teenage use of nicotine products prompts the need to raise awareness of the detrimental effects of developmental nicotine exposure. A more complete understanding of nicotine’s gateway effects during adolescence is critical due to the extremely high and rising economic and societal costs, as well as deaths, associated with substance use. Estimates suggest that drug dependence in the U.S. is associated with over $700 billion in annual costs and more than 64,000 drug overdose deaths in 2016, which is nearly double what was observed the prior decade and continues to climb. We provide evidence for the gateway hypothesis in an effort to build knowledge for Emergency Department clinicians and other healthcare professionals to exhaustively advise their patients and patients’ caretakers. The depth of this understanding, specifically the molecular consequences of adolescent nicotine use, allows for individualized treatment.
plans with a greater emphasis on medication interactions, care coordination, community resources, education, and advocacy. These clinical adjustments may contribute to decreases in addiction and drug-related emergencies.

METHODS

Prior to drafting this manuscript, the two authors independently evaluated and summarized research articles that addressed adolescent substance use and nicotine’s impact on the developing brain and behavior. We conducted a comprehensive review of the literature using a two- to three-word combination of the following keywords: adolescence, substance use, nicotinic acetylcholine receptors, gateway, reward, smoking, tobacco, nicotine, alcohol, psychostimulant, cocaine, amphetamine, cannabis, opioids. We utilized the electronic databases of PubMed and Google Scholar for research articles published in English between January 1968 and November 2018. Articles were included in the review if they discussed nicotine exposure during adolescence, drug sequence patterns, or adolescent substance use. The references from relevant articles and websites of relevant organizations were also examined for other potential sources of information. Out of 80,000 initial search results, approximately 5,000 were reviewed as relevant and non-duplicate articles. To retain focus on adolescent initiation of nicotine products, studies related to maternal tobacco or nicotine exposure were excluded. Studies evaluating other interventions (i.e., medication, sleep, exercise) were also excluded to maintain focus on nicotine’s effects on brain function and behavior. We grouped studies together according to their methodological similarities, so findings without substantial support or reproducibility (i.e., fewer than 5 comparable studies) were excluded. Following exclusion and careful analysis of studies based on key results, limitations, suitability of the methods to test the initial hypothesis, and quality and interpretation of the results obtained, 174 references were selected. The use of two reviewers and two extensive electronic databases allows for a widespread range of research articles, which maximizes scientific credibility and minimizes potential bias.

RESULTS

All Drugs of Abuse Share a Final Common Brain Pathway

Drugs of abuse provide rewarding, pleasurable feelings that contribute to its reinforcement (i.e. repeated use). Reward and reinforcing efficacy are measured in animals with drug self-administration on fixed and progressive ratio schedules of reinforcement, intracranial self-stimulation, oral intake, inhalation, and/or conditioned place preference. Although common drugs of abuse, like marijuana, cocaine, alcohol, and opioids, act on different neurotransmitter systems, they all exert their reinforcing effects via the mesolimbic pathway, a dopaminergic pathway that connects the ventral tegmental area to the nucleus accumbens. The development, projections, and functions of this pathway are strongly influenced by acetylcholine, glutamate, serotonin, and GABA. Dopamine release into the nucleus accumbens regulates motivation and desire for rewarding stimuli and facilitates reward prediction. As nAChRs modulate dopamine release, the gateway hypothesis posits that adolescent nicotine exposure primes the brain’s reward system to enhance the reinforcing efficacy of drugs of abuse.

Nicotine Uniquely Activates the Adolescent Brain Reward System

Substantial epidemiological data suggest that teenagers are more vulnerable than adults to nicotine dependence following minimal tobacco exposure (fewer than seven cigarettes in one month), and individuals who begin smoking during adolescence are more likely to experience difficulty quitting than those who start as adults. Indeed, 90 percent of adult smokers started before age 18. Event-related functional neuroimaging studies in children, adolescents, and adults suggest that children and adolescents have over-reactive reward responses and improved task performance when earning rewards, suggesting enhanced engagement in behaviors that result in immediate gratification. Such factors make adolescents more vulnerable to drug use and abuse.

Animal models allow for experimenter-controlled administration of nicotine and investigation of its direct consequences on the brain and behavior through neuroimaging, biochemical assays, and behavioral tests. Early adolescent rats exposed to intravenous nicotine levels equivalent to one to two cigarettes per day for four days (Figure 1) self-administer a greater amount of cocaine, methamphetamine, and alcohol compared to adolescent rats not exposed to nicotine, as well as compared to exposed and unexposed adults. These data strongly suggest that adolescent nicotine use increases the reinforcing effects of other drugs. In addition, adolescent, but not adult, rodents exposed to nicotine display disruptions in hippocampal learning, long-lasting depressive phenotypes, changes in cocaine sensitivity and reward, enhanced drug-related learning, and deficits in impulse control, executive function, and cognition. Improved drug-related learning following brief nicotine exposure during early adolescence is characterized by rapid initiation and cue association of cocaine and amphetamine self-administration, which is indicative of an addictive-like phenotype and is not observed in adolescent and adult controls or adults also pretreated with nicotine. Furthermore, heightened depressive- and anxiety-like behaviors after 30 days of nicotine abstinence in mice exposed as adolescents, but not adults, indicate that nicotine exposure and withdrawal can have long-term effects on emotional and cognitive functioning, particularly when nicotine exposure occurs during adolescence. The exact timing of exposure during adolescence is also significant, as nicotine’s effects are far greater during early adolescence (PND 28-31 or 12-15 years) versus late adolescence (PND 38-41 or 16-18 years) or adulthood (PND 86-89). Behavioral alterations brought on by developmental nicotine exposure are driven by molecular mechanisms, including epigenetic influences.
Adolescent, but not adult, nicotine exposure in rodents results in the expression of distinct subunits of nAChRs (α5, α6, and β2) and persistent nAChR upregulation in the midbrain, cerebral cortex, and hippocampus. Due to the role of nAChRs in neurotransmitter release and reward processing, alterations in their quantity and function influence reward behavior. In addition, brief nicotine exposure in early adolescent rats enhances cellular activity, dopamine D2 receptor signaling, and serotonin 5-HT receptor function in brain reward areas compared to adult rats also exposed to nicotine. Moreover, chronic nicotine exposure during, but not after, adolescence alters gene expression in the ventral tegmental area and stimulates hyperresponsiveness of dopaminergic nerve terminals in the medial prefrontal cortex. These nicotine-induced changes in reward-related neurotransmitters and brain regions during adolescence may contribute to alterations in reward regulation and behavior.

The changes in brain function and behavior from developmental nicotine exposure are long lasting and a consequence of manipulation of the brain’s reward network, including the prefrontal cortex, nucleus accumbens, ventral tegmental area, hippocampus, and basolateral amygdala. Specifically, adult rodents exposed to nicotine as adolescents show a persistent increase in deltaFosB in the nucleus accumbens, impaired GABA signaling in the ventral tegmental area, and changes in brain morphology and gene expression in reward regions. Furthermore, adult rodents exposed to nicotine as adolescents have an increased preference for cocaine, amphetamine, opioids, and higher doses of nicotine. The following section reviews in greater detail the impacts of adolescent versus adult nicotine exposure on subsequent drug use in animal models. Other drug-associated behaviors are beyond the scope of this review and will not be discussed.

Adolescent Nicotine Exposure Increases Alcohol Consumption

The developments of alcohol and tobacco use patterns are closely related among teenagers, but the order of progression is not universal among cultural and ethnic demographics. Alcohol and nicotine products are more frequently co-abused than consumed separately, as a survey of high school seniors revealed that 88 percent of smokers were drinkers, while 55 percent of nonsmokers were drinkers. However, tobacco use predicts subsequent alcohol use better than the reverse. Individuals who initiate smoking before age 17 are at a higher risk of alcohol abuse and dependence than those who begin after 17. These studies lead to the hypothesis that adolescent exposure to nicotine may lead to enhanced alcohol intake later in life.

Adolescent susceptibility to co-use of nicotine and alcohol is also observed in rodents, as concurrent self-administration of both drugs in adolescent, but not adult, rats is reinforcing and leads to an increase in subsequent oral alcohol intake. Moreover, a different nicotine exposure paradigm promotes long-lasting increases in alcohol self-administration exclusively in nicotine-treated adolescents. Nicotine exposure during adulthood can also change subsequent alcohol consumption, which indicates the influence of nicotine on alcohol reward and reinforcement; however, enhanced alcohol intake is more likely to occur if nicotine is administered prior to alcohol access. These findings collectively indicate that nicotine exposure during adolescence enhances alcohol consumption more than if the same exposure occurs later in life.

Adolescent Nicotine Exposure Increases Psychostimulant Reinforcement and Reward

In humans, adolescent exposure to nicotine influences the likelihood of other psychostimulant use, including cocaine and methamphetamine. Data from a 1994 National Household Survey on Drug Abuse report that individuals who smoked cigarettes before age 15 were up to 80 times more likely to use illegal drugs than those who did not, with cocaine being the most likely drug to be used among young cigarette smokers. A separate study of a cohort representative of the U.S population revealed that the rate of cocaine dependence was highest among cocaine users.
users who initiated cocaine after having smoked cigarettes (20.2 percent), and the rate of dependence was much lower among those who initiated cocaine before smoking (6.3 percent).  

Preclinical studies also demonstrate associations between adolescent nicotine exposure and psychostimulant consumption. Chronic nicotine exposure differentially alters cocaine-induced locomotor activity and intravenous cannabinoid self-administration in adolescent versus adult rodents.  

Adolescent rats exposed to nicotine become considerably more sensitized to the locomotor-activating effects of cocaine compared to non-exposed adolescents. Nicotine exposure during adolescence, but not adulthood, also encourages increased self-administration of cocaine during adulthood, suggesting that nicotine use may carry a greater risk during adolescence than adulthood. The effects of adolescent nicotine pretreatment on psychostimulant reinforcement and locomotor activity are mediated by nAChRs (α7 and α4β2) and serotonergic (5-HT1A) receptors. In addition, chronic and sub-chronic nicotine-exposed adolescent rats experience greater preference for and self-administration of cocaine and methamphetamine versus saline-exposed rats. Pre-adolescent nicotine exposure in rats also leads to increased cocaine-primed reinstatement, a model of relapse behavior. In contrast, alcohol pre-exposure in rats does not influence subsequent cocaine self-administration or cocaine relapse behavior, highlighting the unique gateway effects of nicotine on psychostimulant use.

**Nicotine Interacts With the Endocannabinoid System**

In addition to the enhanced use of alcohol and psychostimulants following early nicotine use, cigarette smoking in adolescents and young adults is associated with earlier onset of cannabis use, more frequent cannabis use, and a larger number of cannabis use disorder symptoms compared to those who did not smoke cigarettes. Likewise, teens who use e-cigarettes or hookah are more than three times more likely to use marijuana, and cannabis users report that nicotine enhances the pleasurable effects of tetrahydrocannabinol (THC), the main psychoactive constituent of marijuana that exerts its effects via cannabinoid receptors. The endocannabinoid system, which comprises cannabinoid receptors (CB1 and CB2) and endogenous ligands (anandamide and 2-Arachidonoylglycerol) throughout the central and peripheral nervous system, plays an important role in cognition, learning and memory, pain relief, emotion, stress, and reward processing.

Although little research has been done on nAChRs interactions with THC specifically during adolescence, preclinical findings in adults suggest that cholinergic and endocannabinoid systems interact to modulate reward-related processes. Selective antagonism of α7 nAChRs in rats blocks the discriminative effects of THC and reduces intravenous self-administration of a cannabinoid CB1 receptor agonist (WIN55,212-2). This association appears to be bidirectional, as blockade of CB1 receptors reduces nicotine self-administration in rats.

THC impacts adolescents and adults distinctively, where adolescent rats experience less of THC’s anxiogenic, aversive, and locomotor-reducing effects than adult rats. Nicotine also facilitates THC’s hypothermic, antinociceptive, and hypolocomotive effects in mice. Sub-chronic nicotine exposure in adolescent rats induces long-lasting effects in cannabinoid CB1 receptors, including increases in the hippocampus and decreases in the striatum. The association between nicotine and cannabis use and the role of reward processing in both the cholinergic and endocannabinoid systems encourages the hypothesis that nicotine may encourage and perpetuate cannabis use.

**Nicotine Interacts With the Opioidergic System**

The endogenous opioid system is primarily involved in pain relief, reward processing, emotion, stress, and autonomic control, and consists of 3 families of receptors: mu, delta, and kappa. Opioid receptors located in the brain and periphery are activated endogenously by enkephalins, dynorphins, endorphins, and endomorphins, as well as exogenously by opioids (e.g., heroin, morphine, oxycodone, fentanyl). Enkephalins, dynorphins, endorphins, endomorphins, and opioids act primarily through mu opioid receptors (MORs) to reduce pain perception, while dynorphins preferentially act at kappa opioid receptors (KORs) to regulate appetite, stress, and emotion. Mu and delta opioid receptors play a critical role in drug reward, whereas the KORs participate in drug aversion.

Although opioid use has not been extensively evaluated during adolescence, an abundance of clinical and preclinical evidence suggests an important bidirectional relationship between nicotine use and opioid reward. There is a significant overlap in the distribution of neuronal nAChRs and opioid receptors. Activation of nAChRs can influence excitability of opioid-containing neurons, and nicotine-induced dopamine release in the nucleus accumbens is dependent on activation of MORs in the ventral tegmental area. Furthermore, nicotine induces a release of endogenous opioids in the brain, and repeated exposure to nicotine can alter expression and/or functioning of opioid receptors.

Perhaps unsurprisingly, given the significant overlap of cholinergic and opioidergic systems, clinical data show that treatment with naloxone and naltrexone, both opioid receptor antagonists, reduces tobacco smoking and craving for tobacco smoke. In addition, opioid-dependent smokers present with more severe nicotine dependence, respond poorly to smoking cessation medications, and may have a higher risk of relapse compared to non-opioid dependent smokers.

The relationship between nicotine and the opioidergic system is similarly substantial in preclinical studies, which is important given the roles of both systems in reward processing. Early adolescent nicotine exposure in mice enhances subsequent morphine reward. In addition, blocking nicotinic receptors reduces rewarding effects of morphine, and activation of MORs decreases nicotine withdrawal symptoms. MOR antagonists increase somatic withdrawal symptoms and
Nicotine Gateway Effects on Adolescent Substance Use

aversion in nicotine-dependent mice and rats, and decrease nicotine self-administration, nicotine preference, and cue-induced reinstatement of nicotine seeking. However, a small number of conflicting studies report no significant differences in nicotine reward, self-administration, or withdrawal following administration of a MOR antagonist, possibly as a result of differences in route of administration, dose, duration, or pharmacodynamics of the antagonist used. Moreover, morphine exhibits significant functional interactions with nAChRs. Chronic nicotine treatment in mice enhances the effect of morphine on striatal dopaminergic pathways, thereby influencing locomotor activity and reinforcement.

Although there are minimal data on nicotine and opioid interactions during adolescence, increasing evidence supports a role of the KOR system in modulating nicotine-associated behaviors. Rodent studies suggest that teen susceptibility to nicotine use is likely due to adolescents finding nicotine more rewarding and less aversive than adults. These differences in sensitivity to nicotine reward and aversion may be, in part, to the KOR system, as activation of KORs increases aversive effects and withdrawal signs of nicotine in adult rodents, but not adolescents. Furthermore, KOR antagonists increase concurrent nicotine and alcohol self-administration in adult, but not adolescent, male rats. Given the interactions between the cholinergic and opioidergic systems in reward regulation and the alarming increases in opioid-related deaths, it is important to recognize and understand risk factors of opioid addiction, including adolescent nicotine exposure.

CONCLUSION

We present epidemiological and clinical findings supporting the gateway hypothesis (Table 1), and emphasize that early adolescent nicotine exposure in various rodent models increases the acquisition and intake of nicotine, alcohol, cocaine, and methamphetamine; co-use of nicotine and alcohol; and the rewarding effects of nicotine, cocaine, methamphetamine, and opioids (Table 2). Although thousands of constituents make up combustible cigarettes, the animal studies highlighted in this review investigate the effects of isolated nicotine, which is more translationally relevant to electronic cigarette use than tobacco/cigarette smoking. This review emphasizes the emerging theme that nicotine hijacks the brain’s reward pathway, particularly during adolescence when the brain is rapidly maturing, by inducing long-term changes in brain chemistry and function.

Nicotine interacts with other neurotransmitter systems and as a result increases the rewarding effects of other drugs by enhanced activation of reward circuitry. Developing brains are incredibly susceptible to long-lasting changes from perturbations during maturation, leading to behavioral changes that continue into adulthood. The prevalence of nicotine use among adolescents and the extensive interactions between nicotinic receptors and drugs of abuse highlight the critical need to better understand how nicotine modulates long-term consequences on brain and behavior related to addiction vulnerability.

This comprehensive review was performed to provide insight into how teenage experimentation with nicotine can induce drastic, ongoing consequences on reward and reinforcement of other drugs of abuse. Alterations in nicotinic acetylcholine receptors are only part of what influence adolescent substance abuse, and the reasons why adolescents decide to use tobacco products and/or nicotine delivery devices need to be further studied. Recognizing adolescent nicotine use as a possible predisposition to addiction to nicotine itself or other substances may decrease illicit drug experimentation and the incidence of drug addiction. Thus, healthcare professionals should take caution when dealing with adolescents with a history of e-cigarette use and continue to inform about its risks. Given the biochemical adaptations as a consequence of adolescent nicotine exposure, physicians may take an individualized approach to treatment and provide additional resources for patients and their families. This increased education and advocacy may improve care coordination and lead to greater adherence to a discharge plan and improved clinical outcomes. Regulatory agencies should continue to establish age limits on the purchase of nicotine products, and increase education and awareness of the risks of smoking and/or vaping during adolescence.

Address for Correspondence: Shahrad Lotfipour, PhD, University of California, Irvine, Department of Emergency Medicine and Pharmaceutical Sciences, 303 Medical Surge II, University of California, Irvine, CA 92697-4625. Email: shahrad@uci.edu.

Conflicts of Interest: By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. This work was supported by the Tobacco Related Disease Research Program grant 22RT-0103A (SL), a Brain and Behavior Research Foundation Grant 21517 (SL), University of California, Irvine, School of Medicine start up fund (SL), Institute for Clinical and Translational Science Pilot Studies Program (NIH/NCATS) (SL), University of California, Irvine, Helping End Addiction Long-term (HEAL) Initiative Opioid-Related Pilot Studies Program from the Institute for Clinical and Translational Science (ICTS), School of Medicine (SOM), Department of Medicine, and Department of Anesthesiology & Perioperative Care (SL), and the University of California, Irvine, Department of Emergency Medicine Pilot Award (SL). There are no other conflicts of interest or sources of funding to declare.

Copyright: © 2019 Ren et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by/4.0/
### Table 1. Summary of epidemiological and clinical findings supporting the gateway hypothesis. Surveys of adolescents and/or young adults were conducted to assess gateway effects of nicotine on subsequent drug use. Details of these selected epidemiological and clinical surveys and findings are highlighted, including age, data source, data analysis, and main observation(s).

| Age                                      | Data source and analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Main observation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Reference(s) |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| 24-25 years (follow-up of former adolescents aged 15-16 years) | Longitudinal cohort of former New York State high school students, followed from grades 10 and 11 (ages 15.7-34.2). Detailed monthly drug use histories were obtained. The following sequence of progression was tested: alcohol, cigarettes, marijuana, other illicit drugs, and prescribed psychoactive drugs. In addition, months of use and non-use of cigarettes and cocaine were identified. | Sequence pattern: Cigarettes preceded marijuana use with or without initial alcohol use among women. However, in men, alcohol consistently preceded marijuana use even in the absence of initial cigarette use. Cigarettes preceded other illicit drugs among women, but not among men. **Cigarette and cocaine use**: Most cocaine users smoked cigarettes before they started using cocaine. In addition, most cocaine users started using cocaine while they were actively smoking cigarettes (i.e., within the same month). | 3,5          |
| 11-16 years                              | Subjects were sampled from eight public schools in Milwaukee, Wisconsin. The subjects were interviewed twice, first during 1979-80 and again during 1981-82. Eighty-nine percent of those interviewed initially were re-interviewed two years later.                                                                                                                                                                                                                                                                                                                                                                                                  | Cigarette use fell on a cumulative (Guttman) scale of use with other drugs (e.g., marijuana, beer, liquor, stimulants, depressants). Having tried substances lower on the Guttman scale made one significantly more likely to be using substances higher on the scale two years later. Use of cigarettes during middle or early high school significantly increased the likelihood that the subject would be using other drugs (e.g., beer, marijuana) two years later.                                                                                     | 4            |
| Years 12-15, 16-17, 18-25, 26-34, 35-49, 50 or over | 1994 National Household Survey on Drug Abuse. Data were analyzed to clarify whether cigarette smoking has any effect on the initiation of illegal drug use.                                                                                                                                                                                                                                                                                                                                                                               | Individuals who had smoked cigarettes were far more likely to use marijuana, cocaine, heroin, and/or crack. Those who smoked cigarettes before age 15 were up to 80 times more likely to use illegal drugs than those who did not. Cocaine was the drug most likely to be used among young cigarette smokers.                                                                                                                     | 5            |
| 16-34 years                              | National Epidemiological Study of Alcohol Related Consequences, a cohort representative of the U.S. population. The rates of lifetime cocaine dependence were compared among three groups: 1) those who had started to use cocaine after they had started to smoke and before they had stopped smoking, 2) those who had started cocaine use before beginning to smoke; and 3) those who had ever smoked 0-100 cigarettes.                                                                                                               | The rate of cocaine dependence was the highest among cocaine users who initiated cocaine after having smoked cigarettes. The rates of dependence were much lower among those who initiated cocaine before smoking or who had ever smoked 0-100 cigarettes.                                                                                                                               | 8            |
| 11-20 years                              | National Longitudinal Study of Adolescent to Adult health data spanning a 14-year period. The relationship between gateway drugs during 11-20 years of age and drug use in adulthood was analyzed using generalized estimating equation regression models.                                                                                                                                                                                                                                                                      | Exposure to marijuana and illegal substances during young adulthood was positively associated with illegal substance and cocaine use. Interactions between the gateway drugs and reporting high depressive symptoms in adolescence or adulthood were associated with increased use of marijuana, illegal drugs, and cocaine in early or young adulthood.                                                                                                                           | 14           |
| 14-30 years                              | Systematic review and meta-analysis of longitudinal studies that assessed initial use of e-cigarettes and subsequent cigarette smoking. Study selection: longitudinal studies reporting odds ratios for cigarette smoking initiation associated with ever use of e-cigarettes or past 30-day cigarette smoking associated with past 30-day e-cigarette use.                                                                                                                                  | E-cigarette use was associated with greater risk for subsequent initiation of cigarette smoking and past 30-day cigarette smoking.                                                                                                                                                                                                                                         | 17           |
Subjects were sampled from 10 public schools in Los Angeles, California. Students completed surveys at baseline (grade 9) and at a 24-month follow-up (grade 11). Associations of baseline e-cigarette, hookah, or combustible cigarette use with ever marijuana use (initiation), current marijuana use (past 30 days), and current dual use of marijuana and tobacco products were examined at the 24-month follow-up.

High schoolers who used e-cigarettes or hookah at baseline compared with those who did not were more likely to report initiation and current use of marijuana as well as dual use of tobacco and marijuana. E-cigarette and hookah use at age 14 years was associated with a 3.6- to 4-fold increase in the odds of initiating and currently using marijuana two years later. The use of e-cigarettes, hookah, and combustible cigarettes in early adolescence more than doubled the odds of currently using both tobacco and marijuana by mid-adolescence.

Table 2. Summary of preclinical studies supporting the gateway hypothesis. Rodent studies highlight nicotine pretreatment paradigms and subsequent observations, including nicotine treatment doses, duration of treatment, species used, age of exposure, behavior tests, and main observation(s).

| Nicotine dose, route of administration, and duration | Species and age of nicotine exposure | Behavior test(s) | Main observation(s) | Reference |
|-----------------------------------------------------|-------------------------------------|------------------|---------------------|-----------|
| 60 μg/kg, IV, 4 days                                | Sprague Dawley rats, PND 28-32 vs. PND 86-90 | IV self-administration of cocaine (0.5 mg/kg/inj), methamphetamine (0.02 mg/kg/inj), or ethanol (1 mg/kg/inj), 1 day each | Adolescent rats pretreated with nicotine had increased initial acquisition of cocaine, methamphetamine, and ethanol compared to saline-treated adolescents and both saline- and nicotine-treated adults. | 86 |
| 0.03 mg/kg/0.1 ml, IV, 2/daily for 4 days          | Sprague Dawley rats, PND 28-32 vs. PND 86-90 | IV self-administration of cocaine (200 or 500 μg/kg/inj), 5 days | Adolescent rats pretreated with nicotine had greater reinforced responding for cocaine compared to saline controls and adults. | 87 |
| 0.4 mg/kg/day, IP, 10 days                         | Sprague Dawley rats, PND 34-43 vs. PND 60-69 | IV self-administration of nicotine (0.04 mg/kg/inj), 15 days | Animals exposed to nicotine during periadolescence self-administered more nicotine than vehicle-exposed animals and animals exposed during postadolescence. | 99 |
| 0.1, 0.5, or 1 mg/kg, SC, 2/daily for either 1 (acute) or 7 (repeated) days | ICR (CD-1) mice, PND 28-34 vs. PND 50-56 | CPP for cocaine (1, 5, or 10 mg/kg, i.p.), morphine (5 mg/kg, s.c.), and amphetamine (0.2 mg/kg, s.c.), 3 days conditioning | Adults exposed to nicotine during early but not late adolescence had increased CPP for cocaine, morphine, and amphetamine. | 103 |
| 0.5 mg/kg, SC, 2/daily, 7 days                      | ICR mice, PND 24-30 | Locomotor activity | Adults exposed to nicotine during early adolescence had enhanced cocaine-induced locomotor sensitization compared to saline-treated animals. | 103 |
| 0.4 mg/kg, IP, 14 days                             | Long-Evans rats, PND 28-42 | Operant ethanol self-administration: 8-day ethanol fading procedure (2-8% v/v) | Adults exposed to nicotine during adolescence had increased ethanol self-administration and altered GABA transmission and chloride homeostasis in the ventral tegmental area compared to adolescent and adult saline exposure and adult nicotine exposure. | 104 |
Nicotine Gateway Effects on Adolescent Substance Use

Ren et al.

Table 2. Continued.

| Dose | Animal Model | Treatment | Outcome |
|------|--------------|-----------|---------|
| 0.1, 0.2, 0.4, 0.8 mg/kg, SC, 10 days | Wistar rats, 150 grams (age not specified) | Operant ethanol self-administration (12% v/v) | Nicotine pretreatment at a higher dose initially suppressed alcohol consumption but stimulated alcohol consumption on repeated treatment. |
| 0.4 mg/kg, IP, 7 days | Sprague-Dawley rats, ~PND 30-37 vs. ~PND 60-67 (based on body weight) | Locomotor activity | Nicotine increased locomotor activity in all animals. Adolescent rats pre-treated with nicotine had sensitization to nicotine-induced repetitive motion over the 7-day nicotine treatment period. Adolescent, but not adult, rats had increased amounts of cocaine-induced repetitive motion after nicotine pretreatment. |
| 0.4 mg/kg, IP, 7 days | Sprague Dawley rats, ~PND 30-37 vs. ~PND 60-67 (based on body weight) | Locomotor activity, IV self-administration of cocaine (descending doses of 1.0, 0.5, 0.25, 0.125, 0.06 mg/kg/inj) | Adult rats exposed to nicotine during early adolescence were sensitized to the locomotor-activating effects of cocaine and self-administered a greater number of cocaine infusions than adolescent rats pretreated with vehicle. |
| 0.4 mg/kg, IP, 10 days | Sprague Dawley rats, PND 35-44 | CPP for cocaine (1 or 3 mg/kg, IP), 12 days alternating cocaine and vehicle | Adult rats that received nicotine treatment during adolescence had enhanced preference for cocaine. |
| 0.16 or 0.64 mg/kg, SC, 16 days | Sprague Dawley rats, PND 35-50 | IV self-administration of methamphetamine (0.05 mg/kg/inj); methamphetamine-primed reinstatement (1 mg/kg, IP) | Nicotine-exposed versus saline-exposed rats obtained more methamphetamine infusions. The high dose of nicotine had no effect on methamphetamine intake and neither nicotine dose altered methamphetamine-primed reinstatement. |
| 0.1 or 0.5 mg/kg, SC, 2/daily, 7 days | ICR mice, PND 28-34 vs. PND 50-57 vs. PND 70-77 | CPP for cocaine, morphine, or amphetamine | Mice treated with nicotine during early adolescence, but not late adolescence or adulthood, showed an increase in CPP for cocaine, morphine, and amphetamine later in adulthood. |

PND, postnatal day; IP, intraperitoneal; IV, intravenous; SC, subcutaneous; Inj, injection; CPP, conditioned place preference; μg, microgram; kg, kilogram; ml, milliliter.

REFERENCES

1. Samet JM. Tobacco smoking: the leading cause of preventable disease worldwide. Thoracic surgery clinics. 2013;23(2):103-12.
2. Kandel D. Stages in adolescent involvement in drug use. Science. 1975;190(4217):912-4.
3. Yamaguchi K and Kandel DB. Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. American Journal of Public Health. 1984;74(7):668-72.
4. Fleming R, Leventhal H, Glynn K, Ershler J. The role of cigarettes in the initiation and progression of early substance use. Addictive Behaviors. 1989;14(3):261-72.
5. Lai S, Lai H, Page JB, McCoy CB. The Association Between Cigarette Smoking and Drug Abuse in the United States. Journal of Addictive Diseases. 2000;19(4):11-24.
6. Degernhardt L, Dierker L, Chiu WT, et al. Evaluating the drug use “gateway” theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend. 2010;108(1-2):84-97.
7. Kandel DB, Yamaguchi K, Chen K. Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol. 1992;53(5):447-57.
8. Levine A, Huang Y, Drisaldi B, et al. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med. 2011;3(107):107-9.
9. Mayet A, Legleye S, Falissard B, Chau N. Cannabis use stages as predictors of subsequent initiation with other illicit drugs among French adolescents: Use of a multi-state model. Addictive Behaviors. 2012;37(2):160-6.
10. Kandel D and Kandel E. The Gateway Hypothesis of substance abuse:
developmental, biological and societal perspectives. *Acta Paediatrica*. 2015;104(2):130-7.

11. Leventhal AM, Strong DR, Kirkpatrick MG, et al. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. *JAMA*. 2015;314(7):700-7.

12. Primack BA, Soneji S, Stoolmiller M, Fine MJ, Sargent JD. Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults. *JAMA Pediatrics*. 2015;169(11):1018-23.

13. Barrington-Trimis JL, Urman R, Berhane K, et al. E-cigarettes and future cigarette use. *Pediatrics*. 2016;138(1):e20160379.

14. Nkansah-Amankra S and Minelli M. “Gateway hypothesis” and early drug use: Additional findings from tracking a population-based sample of adolescents to adulthood. *Prev Med Rep*. 2016;4:134-41.

15. Wills TA, Knight R, Sargent JD, Gibbons FX, Pagano I, Williams RJ. Longitudinal study of e-cigarette use and onset of cigarette smoking among high school students in Hawaii. *Tob Control*. 2017;26:34-39.

16. Miech R, Patrick ME, O’malley PM, Johnston LD. E-cigarette use as a predictor of cigarette smoking: results from a 1-year follow-up of a national sample of 12th grade students. *Tob Control*. 2017;26:e106-e111.

17. Soneji S, Barrington-Trimis JL, Wills TA, et al. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: A systematic review and meta-analysis. *JAMA Pediatrics*. 2017;171(8):788-97.

18. Spindle TR, Hiler MM, Cooke ME, Eissenberg T, Kendler KS, Dick DM. Electronic cigarette use and uptake of cigarette smoking: a longitudinal examination of US college students. *Addict Behav*. 2017;67:66-72.

19. Audrains-McGovern J, Stone MD, Barrington-Trimis J, Unger JB, Leventhal AM. Adolescent E-Cigarette, Hookah, and Conventional Cigarette Use and Subsequent Marijuana Use. *Pediatrics*. 2018;142(3):e20173616.

20. Yuan M, Cross SJ, Loughlin SE, Leslie FM. Nicotine and the adolescent brain. *J Physiol*. 2015;593(16):3397-412.

21. Cross SJ, Lofthouse S, Leslie FM. Mechanisms and genetic factors underlying co-use of nicotine and alcohol or other drugs of abuse. *Am J Drug Alcohol Abuse*. 2017;43(2):171-85.

22. Kandel D and Faust R. Sequence and stages in patterns of adolescent drug use. *Arch Gen Psychiatry*. 1975;32(7):923-32.

23. Whitbeck LB and Armenta BE. Patterns of substance use initiation among Indigenous adolescents. *Addict Behav*. 2015;45:172-9.

24. Miech R, Johnston L, O’Malley P, Bachman J, Schulenberg J. E-cigarettes surpass tobacco cigarettes among teens. *Ann Arbor, Mi: University of Michigan News Service*. 2014.

25. Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the Future National survey results on drug use, 1975-2017: Overview, key findings on adolescent drug use. 2018.

26. Electronic Cigarettes (E-Cigarettes). National Institute on Drug Abuse website. Available at https://www.drugabuse.gov/publications/drgfacts/electronic-cigarettes-e-cigarettes. Accessed August 24, 2018.

27. Cullen KA, Ambrose BK, Gentzkow AS, Apelberg BJ, Jamal A, King BA. Notes from the field: Use of electronic cigarettes and any tobacco product among middle and high school students—United States, 2011–2018. *Morbidity and Mortality Weekly Report*. 2018;67(45):1276.

28. Ambrose BK, Day HR, Rostron B, et al. Flavored tobacco product use among US youth aged 12-17 years, 2013-2014. *JAMA*. 2015;314(17):1871-3.

29. Roditis ML and Halpern-Felsher B. Adolescents’ perceptions of risks and benefits of conventional cigarettes, e-cigarettes, and marijuana: a qualitative analysis. *J Adolesc Health*. 2015;57(2):179-85.

30. Kulik MC, Lisha NE, Glantz SA. E-cigarettes Associated With Depressed Smoking Cessation: A Cross-sectional Study of 28 European Union Countries. *Am J Prev Med*. 2018;54(4):603-9.

31. Watkins S, Glantz SA, Chaffee BW. Association of noncigarette tobacco product use with future cigarette smoking among youth in the population assessment of tobacco and health (path) study, 2013-2015. *JAMA Pediatrics*. 2018;172(2):181-7.

32. Spear LP. The adolescent brain and age-related behavioral manifestations. *Neuropsy Biobehav Rev*. 2000;24(4):417-63.

33. Steinberg L. Risk Taking in Adolescence: What Changes, and Why? *Ann N Y Acad Sci*. 2006;1021(1):51-8.

34. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No,(SMA) 11-4658. *Rockville, MD: Substance Abuse and Mental Health Services Administration*. 2011;201.

35. Lipari R and Jean-Francois B. Trends in Perception of Risk and Availability of Substance Use Among Full-Time College Students. In: *The CBHSQ Report*. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013:1-12.

36. Zoli M, Le Novere N, Hill J, Changeux J. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. *J Neurosci*. 1995;15(3):1912.

37. Broide RS and Leslie FM. The α7 nicotinic acetylcholine receptor in neuronal plasticity. *Mol Neurobiol*. 1999;20(1):1-16.

38. McGeehan DS. Molecular Diversity of Neuronal Nicotinic Acetylcholine Receptors. *Ann N Y Acad Sci*. 2006;688(1):565-77.

39. Hellström-Lindahl E and Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. *Behav Brain Res*. 2000;113(1):159-68.

40. Hogg R, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. In: *Rev Physiol Biochem Pharmacol*. Springer; 2003:1-46.

41. Gott C and Clementi F. Neuronal nicotinic receptors: from structure to pathology. *Prog Neurobiol*. 2004;74(6):363-96.

42. Gott C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. *Trends Pharmacol Sci*. 2006;27(9):482-91.

43. Pentel PR, Keyler DE, Chen Y, et al. Vaccination against nicotine does not prevent nicotine-induced changes in fetal nicotinic receptor binding and c-fos mRNA expression in rats. *Neurotoxicol Teratol*. 2006;28(5):589-96.

44. Dani JA and Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu Rev..."
Nicotine Gateway Effects on Adolescent Substance Use  
Ren et al.

Pharmacol Toxicol. 2007;47:699-729.

45. Campbell NR, Fernandes CC, Hallf AW, Berg DK. Endogenous signaling through α7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus. J Neurosci. 2010;30(26):8734-44.

46. Wada E, Wada K, Boulter J, et al. Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol. 1989;284(2):314-35.

47. Marks MJ, Pauly JR, Gross SD, et al. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci. 1992;12(7):2765-84.

48. Clarke PB. Nicotinic receptors in mammalian brain: localization and relation to cholinergic innervation. Prog Brain Res. 1993;98:77-77.

49. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic receptor subtype expressed on dopaminergic terminals in the rat striatum. J Neurosci. 2002;22(20):8785-9.

50. Van de Kamp JL and Collins AC. Prenatal nicotine alters nicotinic receptor development in the mouse brain. Pharmacol Biochem Behav. 1994;47(4):889-900.

51. Aramakis VB, Hsieh CY, Leslie FM, Metherate R. A critical period for nicotine-induced disruption of synaptic development in rat auditory cortex. J Neurosci. 2000;20(16):6106-16.

52. Adriani W, Macri S, Pacifici R, Laviola G. Peculiar vulnerability to nicotine oral self-administration in mice during early adolescence. Neuropsychopharmacology. 2002;27(2):212-24.

53. Silberg J, Rutter M, D’Onofrio B, Rutter M, D’Onofrio B, Eaves L. Genetic and environmental risk factors in adolescent substance use. J Child Psychol Psychiatry. 2003;44(5):664-76.

54. Charles NE, Mathias CW, Acheson A, et al. Increased Pre- and Early-Adolescent Stress in Youth with a Family History of Substance Use Disorder and Early Substance Use Initiation. J Youth Adolesc. 2015;44(10):1954-67.

55. Bayer SA, Altman J, Russo RJ, Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology. 1993;14(1):83-144.

56. Quinn R. Comparing rat’s to human’s age: how old is my rat in people years? Nutrition. 2005;21(6):775-7.

57. Hedegaard H, Warner M, Minño AM. Drug overdose deaths in the United States, 1999-2015. NCHS data brief, no 273. Hyattsville, MD: National Center for Health Statistics. 2017.

58. Overdose Death Rates. National Institute on Drug Abuse website. Available at http://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed June 18, 2018.

59. Department of Health and Human Services. Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. 2012.

60. Di Chiara G and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274-8.

61. Koob GF and Le Moal M. Drug Addiction, Dysregulation of Reward, and Allostasis. Neuropsychopharmacology. 2001;24:97-129.

62. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci. 2001;2:119-28.

63. Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47:227-41.

64. Volkow ND, Fowler JS, Wang G-J, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9:557-69.

65. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004;5:483-94.

66. Balfour DJK. The Neuronal Pathways Mediating the Behavioral and Addictive Properties of Nicotine. In: Henningfield JE, London ED, Pogun S, eds. Nicotine Psychopharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009:209-233.

67. Tseng KY and O’Donnell P. D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex. Synapse. 2007;61(10):843-50.

68. O’Donnell P. Adolescent maturation of cortical dopamine. Neurotox Res. 2010;18(3-4):306-12.

69. Tseng KY, O’Donnell P. Post-pubertal emergence of prefrontal cortical up states induced by D1–NMDA co-activation. Cereb Cortex. 2004;15(1):49-57.

70. Flores-Barrera E, Thomases DR, Heng L-J, Cass DK, Caballero A, Tseng KY. Late adolescent expression of GluN2B transmission in the prefrontal cortex is input-specific and requires postsynaptic protein kinase A and D1 dopamine receptor signaling. Biol Psychiatry. 2014;75(6):508-16.

71. Huppe-Gourgue F and O’Donnell P. Periadolescent changes of D2–AMPA interactions in the rat nucleus accumbens. Synapse. 2012;66(1):1-8.

72. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593-9.

73. Floresco SB. The Nucleus Accumbens: An Interface Between Cognition, Emotion, and Action. Annu Rev Psychol. 2015;66(1):25-52.

74. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 1997;390:401-4.

75. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393(1):295-314.

76. Cui C, Booker TK, Allen RS, et al. The β3 Nicotinic Receptor Subunit: A Component of α-Conotoxin MII-Binding Nicotinic Acetylcholine Receptors that Modulate Dopamine Release and Related Behaviors. J Neurosci. 2003;23(35):11045-53.

77. Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. Neuroscience. 2004;144(4):1347-60.

78. Breslau N and Peterson EL. Smoking cessation in young adults: age at initiation of cigarette smoking and other suspected influences. Am J Public Health. 1996;86(2):214-20.

79. DiFranza JR, Savageau JA, Fletcher K, et al. Symptoms of tobacco dependence after brief intermittent use: The development and assessment of nicotine dependence in youth—2 study. Arch Pediatr Adolesc Med. 2007;161(7):704-10.
80. Chen J and Millar WJ. Age of smoking initiation: implications for quitting. Health Rep. 1998;9:39-48.
81. Khuder SA, Dayal HH, Mutgi AB. Age at smoking onset and its effect on smoking cessation. Addict Behav. 1999;24(5):673-7.
82. Kandel DB and Chen K. Extent of smoking and nicotine dependence in the United States: 1991–1993. Nicotine Tob Res. 2000;2(3):263-74.
83. Cengelli S, O’Loughlin J, Lauzon B, Comuz J. A systematic review of longitudinal population-based studies on the predictors of smoking cessation in adolescent and young adult smokers. Tob Control. 2012;21:355-62.
84. Kendler KS, Ohlsson H, Sundquist K, Sundquist J. Peer deviance, parental divorce, and genetic risk in the prediction of drug abuse in a nationwide Swedish sample: evidence of environment-environment and gene-environment interaction. JAMA Psychiatry. 2014;71(4):439-45.
85. Padmanabhan A, Geier CF, Ordaz SJ, Teslovich T, Luna B. Developmental changes in brain function underlying the influence of reward processing on inhibitory control. Dev Cogn Neurosci. 2011;1(4):517-29.
86. Dao JM, McQuown SC, Loughlin SE, Belluzzi JD, Leslie FM. Nicotine Alters Limbic Function in Adolescent Rat by a 5-HT1A Receptor Mechanism. Neuropsychopharmacology. 2011;36(7):1319-31.
87. McQuown SC, Belluzzi JD, Leslie FM. Low dose nicotine treatment during early adolescence increases subsequent cocaine reward. Neurotoxicol Teratol. 2007;29(1):66-73.
88. Kenney JW, Adoff MD, Wilkinson DS, Gould TJ. The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology. 2011;217(3):353-65.
89. Holliday ED, Nucero P, Kutlu MG, et al. Long-term effects of chronic nicotine on emotional and cognitive behaviors and hippocampus cell morphology in mice: comparisons of adult and adolescent nicotine exposure. Eur J Neurosci. 2016;44(10):2818-28.
90. Kelley BM and Rowan JD. Long-term, low-level adolescent nicotine exposure produces dose-dependent changes in cocaine sensitivity and reward in adult mice. Int J Dev Neurosci. 2004;22(5):339-48.
91. Fountain SB, Rowan JD, Kelley BM, Willey AR, Nolley EP. Adolescent exposure to nicotine impairs adult serial pattern learning in rats. Exp Brain Res. 2008;187(4):651-6.
92. Mojica CY, Belluzzi JD, Leslie FM. Age-dependent alterations in reward-seeking behavior after brief nicotine exposure. Psychopharmacology. 2014;231(8):1763-73.
93. Counotte DS, Spijker S, Van de Burgwal LH, et al. Long-lasting cognitive deficits resulting from adolescent nicotine exposure in rats. Neuropsychopharmacology. 2009;34(2):299-306.
94. Cortright JJ, Sampredo GR, Neugebauer NM, Vezina P. Previous Exposure to Nicotine Enhances the Incentive Motivational Effects of Amphetamine via Nicotine-Associated Contextual Stimuli. Neuropsychopharmacology. 2012;37(10):2277-84.
95. Kawai HD, Kang H-A, Metherate R. Heightened nicotinic regulation of auditory cortex during adolescence. J Neurosci. 2011;31(40):14367-77.
96. Huang Y-Y, Kandel DB, Kandel ER, Levine A. Nicotine primes the effect of cocaine on the induction of LTP in the amygdala. Neuropharmacology. 2013;74:126-34.
97. Huang Y-Y, Levine A, Kandel DB, et al. D1/D5 receptors and histone deacetylation mediate the Gateway Effect of LTP in hippocampal dentate gyrus. Learn Mem. 2014;21(3):153-60.
98. Trauth JA, Seidler F, McCook E, Slotkin T. Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. Brain Res. 1999;851(1-2):3-19.
99. Adriani W, Spijker S, Deroche-Gamonet V, et al. Evidence for Enhanced Neurobehavioral Vulnerability to Nicotine during Periadolescence in Rats. J Neurosci. 2003;23(11):4712-6.
100. Mojica CY, Dao JM, Yuan M, Loughlin SE, Leslie FM. Nicotine modulation of adolescent dopamine receptor signaling and hypothalamic peptide response. Neuropsychopharmacology. 2014;77:285-93.
101. Doura MB, Luu TV, Lee NH, Perry DC. Persistent gene expression changes in ventral tegmental area of adolescent but not adult rats in response to chronic nicotine. Neuroscience. 2010;170(2):503-13.
102. Counotte DS, Giorgiouna NA, Li KW, et al. Lasting synaptic changes underlie attention deficits caused by nicotine exposure during adolescence. Nat Neurosci. 2011;14:417-9.
103. Alajaj M, Lazenka MF, Kota D, et al. Early adolescent nicotine exposure affects later-life cocaine reward in mice. Neuropharmacology. 2016;105:308-17.
104. Thomas AM, Ostroumov A, Kimmey BA, et al. Adolescent Nicotine Exposure Alters GABAA Receptor Signaling in the Ventral Tegmental Area and Increases Adult Ethanol Self-Administration. Cell Rep. 2018;23(1):68-77.
105. Kutlu MG, Tumolo JM, Holliday E, Garrett B, Gould TJ. Acute nicotine enhances spontaneous recovery of contextual fear and changes c-fos early gene expression in infralimbic cortex, hippocampus, and amygdala. Learn Mem. 2016;23(8):405-14.
106. Wetzelis JLL, Kremers SPJ, Vitória PD, De Vries H. The alcohol–tobacco relationship: a prospective study among adolescents in six European countries. Addiction. 2003;98(12):1755-63.
107. Department of Health and Human Services USA. Preventing Tobacco Use among Young People: A Report of the Surgeon General. US Department of Health and Human Services: 1994.
108. Sobell M, Sobell L, Kozlowski L, Fertig J, Allen J. Alcohol and tobacco: from basic science to clinical practice. National Institutes of Health. 1995:207-24.
109. Grant BF. Age at smoking onset and its association with alcohol consumption and DSM-IV alcohol abuse and dependence: Results from the national longitudinal alcohol epidemiologic survey. J Subst Abuse. 1998;10(1):59-73.
110. John U, Meyer C, Rumpf H, Hapke U. Probabilities of alcohol high-risk drinking, abuse or dependence estimated on grounds of tobacco smoking and nicotine dependence. Addiction. 2003;98(6):805-14.
111. Riala K, Hakko H, Isomalli M, Järvelin M-R, Räsänen P. Teenage smoking and substance use as predictors of severe alcohol problems in late adolescence and in young adulthood. J Adolesc Health. 2004;35(3):245-54.
112. Lárraga A, Belluzzi JD, Leslie FM. Nicotine Increases Alcohol Intake in Adolescent Male Rats. Front Behav Neurosci. 2017;11:25.
Nicotine Gateway Effects on Adolescent Substance Use

Ren et al.

113. Le AD, Corrigall WA, Harding JW, Juzytsch W, Li TK. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res. 2000;24(2):155-63.

114. Collins SL and Izenwasser S. Chronic nicotine differentially alters cocaine-induced locomotor activity in adolescent vs. adult male and female rats. Neopharmacology. 2004;46(3):349-62.

115. McQuown SC, Dao JM, Belluzzi JD, Leslie FM. Age-dependent effects of low-dose nicotine treatment on cocaine-induced behavioral plasticity in rats. Psychopharmacology. 2009;207(1):143-52.

116. Reed SC and Izenwasser S. Nicotine produces long-term increases in cocaine reinforcement in adolescent but not adult rats. Brain Res. 2017;1654(Pt B):165-70.

117. McMillen BA, Davis BJ, Williams HL, Soderstrom K. Periadolescent nicotine exposure causes heterologous sensitization to cocaine reinforcement. Eur J Pharmacol. 2005;509(2):161-4.

118. Pipkin JA, Kaplan GJ, Plant CP, et al. Nicotine exposure beginning in adolescence enhances the acquisition of methamphetamine self-administration, but not methamphetamine-primed reinstatement in male rats. Drug Alcohol Depend. 2014;138:341-4.

119. Anker JJ and Carroll ME. Adolescent nicotine exposure sensitizes cue-induced reinstatement of cocaine seeking in rats bred for high and low saccharin intake. Drug Alcohol Depend. 2011;118(1):68-72.

120. Fredriksson I, Adhikary S, Steensland P, et al. Prior Exposure to Alcohol Has No Effect on Cocaine Self-Administration and Relapse in Rats: Evidence from a Rat Model that Does Not Support the Gateway Hypothesis. Neuropsychopharmacology. 2017;42(5):1001-11.

121. Huizink AC, Levälahti E, Korhonen T, et al. Tobacco, Cannabis, and Other Illicit Drug Use Among Finnish Adolescent Twins: Causal Relationship or Correlated Liabilities? J Stud Alcohol Drugs. 2010;71(1):5-14.

122. Dierker L, Braymiller J, Rose J, Goodwin R, Selya A. Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults. Drug Alcohol Depend. 2018;187:212-20.

123. Amos A, Wiltshire S, Bostock Y, Haw S, McNeill A. ‘You can’t go without it...you need it for your hash’—a qualitative exploration of smoking, adolescents and young adults. Addict Res Theory. 2018;26(2):157-166.

124. Barik J and Wonnacott S. Molecular and Cellular Mechanisms of Action of Nicotine in the CNS. In: Henningfield JE, London ED, Pogun S, eds. Nicotine Psychopharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009:173-207.

125. Valjent E, Mitchell JM, Besson M-J, Caboche J, Maldonado R. Delta9-tetrahydrocannabinol and nicotine. Br J Pharmacol. 2002;135(2):564-78.

126. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids (PLEFA). 2002;66(2):269-85.

127. Balero GN, Aso E, Berrendero F, Muntra P, Maldonado R. Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci. 2004;20(10):2737-48.

128. Solinas M, Scherma M, Fattore L, et al. Nicotinic α4 receptors as a new target for treatment of cannabis abuse. J Neurosci. 2007;27(21):5615-20.

129. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002;13(5):451-63.

130. Chemer JS, Wassum KM, Sommers LA, et al. Phasic Dopamine Release Evoked by Abused Substances Requires Cannabinoid Receptor Activation. J Neurosci. 2007;27(4):791-5.

131. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology. 2007;191(4):867-77.

132. Marco EM, Granström O, Moreno E, et al. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur J Pharmacol. 2007;557(1):37-43.

133. Benbarroch EE. Endogenous opioid systems. Neurology. 2012;79(8):807-14.

134. Shippenberg TS and Herz A. Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr. 1986;75:563-6.

135. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89(4):1379-412.

136. Pradhan AA, Befort K, Nozaki C, Gavéraux-Ruff C, Kieffer BL. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci. 2011;32(10):581-90.

137. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends in neurosciences. 1995;18(1):22-9.

138. Barik J and Wonnacott S. Molecular and Cellular Mechanisms of Action of Nicotine in the CNS. In: Henningfield JE, London ED, Pogun S, eds. Nicotine Psychopharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009:173-207.

139. Tanda G and Di Chiara G. A dopamine-μ1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psycho stimulant drugs of abuse. Eur J Neurosci. 1998;10(3):1179-87.

140. Davenport KE, Houdi AA, Van Loon GR. Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett. 1990;113(1):40-6.

141. Walters CL, Cleck JL, Kuo Y, Blendy JA. μ-Opioid Receptor and CRED Activation Are Required for Nicotine Reward. Neuron. 2005;46(6):933-43.

142. Galeote L, Kieffer BL, Maldonado R, Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antagonism in mice. J Neurophysiol. 2004;91(2):526-44.

143. Ren et al. Nicotine Gateway Effects on Adolescent Substance Use. White Journal of Emergency Medicine. 2019;5:708.
affects ad libitum smoking behavior. Psychopharmacology (Berl). 1998;140(2):185-90.

147. Parker MA, Streck JM, Sigmon SC. Associations between opioid and nicotine dependence in nationally representative samples of United States adult daily smokers. Drug Alcohol Depend 2018;186:167-70.

148. Gyudish J, Passalacqua E, Tajima B, Chan M, Chun J, Bostrom A. Smoking Prevalence in Addiction Treatment: A Review. Nicotine Tob Res. 2011;13(6):401-11.

149. Miller ME and Sigmon SC. Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions. Nicotine Tob Res. 2015;17(8):955-9.

150. Talka R, Tuominen RK, Salminen O. Methadone’s effect on nAChRs—a link between methadone use and smoking? Biochem Pharmacol. 2015;97(4):542-9.

151. Kota D, Alajaji M, Bagdas D, Selley DE, Sim-Selley LJ, Damaj MI. Early adolescent nicotine exposure affects later-life hippocampal μ-opioid receptors activity and morphine reward but not physical dependence in male mice. Pharmacol Biochem Behav. 2018;173:58-64.

152. Zarrindast M-R, Faraji N, Rostami P, Shahraei H, Ghoshouni H. Cross-tolerance between morphine-and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav. 2003;74(2):363-9.

153. Feng B, Xing J, Jia D, et al. Blocking α4β2 and α7 nicotinic acetylcholine receptors inhibits the reinstatement of morphine-induced CPP by drug priming in mice. Behav Brain Res. 2011;220(1):100-5.

154. Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology. 1993;112(2-3):339-42.

155. Ise Y, Narta M, Nagase H, Suzuki T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacology. 2000;151(1):49-54.

156. Watkins SS, Stinus L, Koob GF, Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther. 2000;292(3):1053-64.

157. Ismayilova N and Shoaib M. Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats. Psychopharmacology. 1996;127(1):146-53.

158. Liu X and Jernigan C. Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):146-53.

159. Göktayl G, Cauven S, Levendusky MC, Hamilton JR, Millington WR. Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal. Eur J Pharmacol. 2006;530(1-2):95-102.

160. Liu X, Palmatier MI, Caggiula AR, et al. Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology. 2009;202(4):589.

161. Corrigall WA and Coen KM. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol Biochem Behav. 1991;39(3):799-802.

162. DeNoble VJ and Mele PC. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology. 2006;184(3):266-72.

163. Talka R, Salminen O, Whiteaker P, Lukas RJ, Tuominen RK. Nicotine–morphine interactions at α4β2, α7 and α3(⁎) nicotinic acetylcholine receptors. Eur J Pharmacol. 2013;701(1):57-64.

164. Vihavainen T, Reilander TR, Leiviskä R, et al. Chronic nicotine modifies the effects of morphine on extracellular striatal dopamine and ventral tegmental GABA. J Neurochem 2006;107(3):844-54.

165. Vastola BJ, Douglas LA, Varlinskaya EI, Spear LP. Nicotine-induced conditioned place preference in adolescent and adult rats. Physiol Behav. 2002;77(1):107-14.

166. Belluzzi JD, Lee AG, Oliff HS, Leslie FM. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. Psychopharmacology. 2004;174(3):389-95.

167. Wilmouth CE and Spear LP. Adolescent and Adult Rats’ Aversion to Flavors Previously Paired with Nicotine. Ann N Y Acad Sci. 2006;1021(1):462-4.

168. Shram MJ, Funk D, Li Z, Lê AD. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine. Psychopharmacology. 2006;186(2):201.

169. Brielmaier JM, McDonald CG, Smith RF. Immediate and long-term behavioral effects of a single nicotine injection in adolescent and adult rats. Neurotoxicol Teratol. 2007;29(1):74-80.

170. Torres OV, Tejeda HA, Natividad LA, O’Dell LE. Enhanced vulnerability to Flavors Previously Paired with Nicotine in Rats. Ann N Y Acad Sci. 2008;1133(1):24-34.

171. Cao J, Belluzzi JD, Loughlin SE, Dao JM, Chen Y, Leslie FM. Locomotor and Stress Responses to Nicotine Differ in Adolescent and Adult Rats. Psychopharmacology. 2010;210(2):285-94.

172. Ward M, Norman H, D’Souza MS. Effects of pharmacological manipulation of the kappa opioid receptors on the aversive effects of nicotine. Behav Brain Res. 2018;338:56-65.

173. Jackson KJ, Carroll FI, Negus SS, Damaj MI. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinoceception, reward, and withdrawal in the mouse. Psychopharmacology. 2010;210(2):285-94.

174. Anderson RI, Morales M, Spear LP, Varlinskaya EI. Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats. Psychopharmacology. 2014;231(8):1687-93.